{"filing":{"accession_number":"0001628280-26-045350","cik":"0001077183","ticker":"NEO","company_name":"NEOGENOMICS INC","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"neo-20260623.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1077183/000162828026045350/neo-20260623.htm"},"events":[{"id":13700,"run_id":12168,"accession_number":"0001628280-26-045350","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"NeoGenomics appointed Carolyn S. Starrett as a director to fill a newly created board vacancy, effective June 23, 2026. Ms. Starrett brings 25+ years of executive experience, including a decade as CEO of Flatiron Health and prior roles at Foundation Medicine and Boston Consulting Group, making this a material addition to the Board's composition and expertise.","company_name":"NEOGENOMICS INC","ticker":"NEO","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":10917,"accession_number":"0001628280-26-045350","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Carolyn S. Starrett as a director to fill a newly created board vacancy, effective immediately on June 23, 2026. The principal disclosed action is a person taking a role on the Board of Directors. Ms. Starrett brings significant executive experience from her tenure as CEO of Flatiron Health and prior roles at Foundation Medicine and Boston Consulting Group, making this a material governance event affecting the composition and expertise of the Board.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T11:11:50.419696+00:00","company_name":"","ticker":null,"filing_date":""},{"id":10918,"accession_number":"0001628280-26-045350","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Carolyn Starrett to NeoGenomics' Board of Directors, announced via press release on June 25, 2026. Ms. Starrett brings 25+ years of experience including a decade at Flatiron Health as CEO and Board Director, making her a significant addition to the board. Board appointments of experienced executives are material governance events affecting investor assessment of the company's leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T11:11:50.419696+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10917,"accession_number":"0001628280-26-045350","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Carolyn S. Starrett as a director to fill a newly created board vacancy, effective immediately on June 23, 2026. The principal disclosed action is a person taking a role on the Board of Directors. Ms. Starrett brings significant executive experience from her tenure as CEO of Flatiron Health and prior roles at Foundation Medicine and Boston Consulting Group, making this a material governance event affecting the composition and expertise of the Board.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T11:11:50.419696+00:00","company_name":"NEOGENOMICS INC","ticker":"NEO","filing_date":"2026-06-25"},{"id":10918,"accession_number":"0001628280-26-045350","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Carolyn Starrett to NeoGenomics' Board of Directors, announced via press release on June 25, 2026. Ms. Starrett brings 25+ years of experience including a decade at Flatiron Health as CEO and Board Director, making her a significant addition to the board. Board appointments of experienced executives are material governance events affecting investor assessment of the company's leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T11:11:50.419696+00:00","company_name":"NEOGENOMICS INC","ticker":"NEO","filing_date":"2026-06-25"}]}